Outlook Therapeutics Partners With Mediconsult AG For Exclusive Swiss Distribution Of LYTENAVA™ (Bevacizumab Gamma) In Retina Disease Treatment

Outlook Therapeutics, Inc., a biopharmaceutical company focused on improving the standard of care for bevacizumab in the treatment of retinal diseases, has entered into an exclusive commercial distribution agreement with Mediconsult AG, Switzerland’s leading full-service partner for ophthalmic professionals. The agreement covers the sale and distribution of LYTENAVA™ (bevacizumab gamma) in the Swiss market.

Under this agreement, Mediconsult will have exclusive rights to market, import, distribute, and commercialize LYTENAVA™ in Switzerland under the Outlook Therapeutics trademark. Mediconsult will also manage regulatory activities within the country, including seeking and maintaining Marketing Authorization, while leading other commercialization efforts. Outlook Therapeutics will continue to oversee manufacturing, product supply, and the protection of all related intellectual property.

Bob Jahr, Chief Executive Officer of Outlook Therapeutics, noted that Switzerland represents an important European market for LYTENAVA™ and expressed confidence in Mediconsult’s expertise. He highlighted that the partnership aligns with Outlook Therapeutics’ strategy to expand access to LYTENAVA™ across Europe, while ensuring full control over manufacturing and product quality.

Mediconsult AG brings over 35 years of experience in ophthalmology and has a proven track record of successfully navigating the Swiss regulatory and commercial landscape. The company has deep knowledge of the local market and long-standing relationships with key stakeholders in the ophthalmology community.

Thomas Sammer, Ph.D., Chief Executive Officer of Mediconsult AG, said the partnership reflects their commitment to providing patients and physicians in Switzerland with new treatment options. He emphasized that LYTENAVA™ represents an important therapy for patients with wet age-related macular degeneration (AMD) and expressed confidence that Mediconsult’s regulatory and commercial expertise will support a successful launch in the Swiss market. LYTENAVA™ is expected to become available in Switzerland in 2027, subject to the receipt of Marketing Authorization.